Boston Scientific Co. (NYSE:BSX) SVP Wendy Carruthers sold 29,412 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $39.63, for a total transaction of $1,165,597.56. Following the sale, the senior vice president now directly owns 200,751 shares in the company, valued at approximately $7,955,762.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
NYSE:BSX opened at $40.26 on Wednesday. Boston Scientific Co. has a 1-year low of $26.27 and a 1-year high of $41.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.56 and a current ratio of 0.76. The firm has a market capitalization of $54.76 billion, a P/E ratio of 27.39, a PEG ratio of 2.30 and a beta of 0.83.
Get Boston Scientific alerts:Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.02. The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.57 billion. Boston Scientific had a net margin of 17.01% and a return on equity of 25.92%. Boston Scientific’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm posted $0.34 EPS. Analysts forecast that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.
A number of analysts have weighed in on the stock. Argus raised their price objective on shares of Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $45.00 target price on shares of Boston Scientific in a report on Monday, February 11th. SunTrust Banks reaffirmed a “buy” rating and issued a $47.00 target price on shares of Boston Scientific in a report on Friday, February 8th. Guggenheim reaffirmed a “buy” rating and issued a $48.00 target price on shares of Boston Scientific in a report on Friday, February 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a report on Wednesday, February 6th. Three investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.54.
Several hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. boosted its position in shares of Boston Scientific by 0.8% during the 4th quarter. American Century Companies Inc. now owns 4,136,750 shares of the medical equipment provider’s stock worth $146,193,000 after purchasing an additional 34,818 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific during the 4th quarter worth $468,943,000. Actinver Wealth Management Inc. purchased a new stake in shares of Boston Scientific during the 4th quarter worth $250,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Boston Scientific during the 4th quarter worth $967,000. Finally, B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund purchased a new stake in shares of Boston Scientific during the 4th quarter worth $598,000. Institutional investors own 91.34% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Boston Scientific Co. (BSX) SVP Wendy Carruthers Sells 29,412 Shares” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/4217530/boston-scientific-co-bsx-svp-wendy-carruthers-sells-29412-shares.html.About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: Gap Up Stocks
No comments:
Post a Comment